Compass Therapeutics Statistics
Total Valuation
CMPX has a market cap or net worth of $139.35 million. The enterprise value is -$14.47 million.
| Market Cap | 139.35M |
| Enterprise Value | -14.47M |
Important Dates
The last earnings date was Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CMPX has 180.09 million shares outstanding. The number of shares has increased by 27.73% in one year.
| Current Share Class | 180.09M |
| Shares Outstanding | 180.09M |
| Shares Change (YoY) | +27.73% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.86% |
| Owned by Institutions (%) | 77.13% |
| Float | 132.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 783.85 |
| PB Ratio | 0.98 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.79, with a Debt / Equity ratio of 0.06.
| Current Ratio | 6.79 |
| Quick Ratio | 6.69 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.04% and return on invested capital (ROIC) is -31.67%.
| Return on Equity (ROE) | -49.04% |
| Return on Assets (ROA) | -28.98% |
| Return on Invested Capital (ROIC) | -31.67% |
| Return on Capital Employed (ROCE) | -62.66% |
| Weighted Average Cost of Capital (WACC) | 9.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.21M |
| Employee Count | 39 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.21% in the last 52 weeks. The beta is 1.06, so CMPX's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | -84.21% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 2.93 |
| Relative Strength Index (RSI) | 37.22 |
| Average Volume (20 Days) | 2,068,173 |
Short Selling Information
The latest short interest is 40.79 million, so 22.65% of the outstanding shares have been sold short.
| Short Interest | 40.79M |
| Short Previous Month | 41.84M |
| Short % of Shares Out | 22.65% |
| Short % of Float | 30.80% |
| Short Ratio (days to cover) | 8.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -94.07M |
| Pretax Income | -86.36M |
| Net Income | -86.36M |
| EBITDA | -93.99M |
| EBIT | -94.07M |
| Earnings Per Share (EPS) | -$0.46 |
Balance Sheet
The company has $163.06 million in cash and $9.23 million in debt, with a net cash position of $153.82 million or $0.85 per share.
| Cash & Cash Equivalents | 163.06M |
| Total Debt | 9.23M |
| Net Cash | 153.82M |
| Net Cash Per Share | $0.85 |
| Equity (Book Value) | 142.57M |
| Book Value Per Share | 0.79 |
| Working Capital | 141.13M |
Cash Flow
In the last 12 months, operating cash flow was -$61.58 million and capital expenditures -$364,000, giving a free cash flow of -$61.94 million.
| Operating Cash Flow | -61.58M |
| Capital Expenditures | -364,000 |
| Depreciation & Amortization | 81,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -61.94M |
| FCF Per Share | -$0.34 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CMPX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -27.73% |
| Shareholder Yield | -27.73% |
| Earnings Yield | -59.91% |
| FCF Yield | -44.45% |
Analyst Forecast
The average price target for CMPX is $5.26, which is 580.28% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.26 |
| Price Target Difference | 580.28% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |